Rigel Announces Five Presentations at the EHA2024 Hybrid Congress

Core Insights - Rigel Pharmaceuticals presented five-year efficacy data for REZLIDHIA® (olutasidenib) at the EHA 2024 Hybrid Congress, demonstrating its effectiveness in treating relapsed or refractory (R/R) mutated isocitrate dehydrogenase-1 (mIDH1) acute myeloid leukemia (AML) [1][5][6] Group 1: Efficacy Data - The oral presentation highlighted that 35% of 147 efficacy evaluable patients achieved complete remission (CR) or CR with partial hematologic recovery (CRh), with a median time to CR/CRh of 1.9 months and a median duration of 25.3 months [6] - In patients previously treated with venetoclax, 33% achieved CR/CRh, with a median overall survival of 16.2 months [7] - The overall response rate (ORR) was 48%, with a median duration of 15.5 months and a maximum duration ongoing at 54.6 months [6][9] Group 2: Safety and Tolerability - Olutasidenib was reported to have a well-characterized and manageable safety profile, with differentiation syndrome occurring in 16% of patients [13][14] - The treatment was generally well tolerated in elderly patients, with 31% achieving CR/CRh in a subgroup analysis of patients aged 75 and older [10] Group 3: Subgroup Analyses - Data presented included the efficacy of olutasidenib in elderly patients, those who failed prior venetoclax treatment, and as a bridge to allogeneic hematopoietic stem cell transplantation (HSCT) [4][10][11] - In patients with mIDH1 AML secondary to myeloproliferative neoplasms (MPN), 40% achieved CR, with a median duration of response of 15.6 months [8][11] Group 4: Future Implications - The data supports the potential of REZLIDHIA in treating patient populations with limited treatment options, particularly those with mIDH1 AML secondary to MPN [5][12] - The findings suggest that olutasidenib may serve as a bridge to allogeneic stem cell transplantation for previously ineligible patients, with 75% of those proceeding to transplant achieving CR/CRh prior to the procedure [11]